177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers
Prostate-specific membrane antigen (PSMA) is a zinc metalloenzyme belonging to the family of type II transmembrane protein; it is also known as Glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or Folate Hydrolase 1, and it is encoded by the FOLH1 (folate hydrolase 1) gene [1]. PSMA has been found to be expressed in several human tissues, such as prostate, nervous system, salivary glands, small intestine, and kidney, but its expression has been observed also in pathological conditions such as prostate cancer (PCa) and tumor-associated neovasculature [2 –5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi Source Type: research